Crocs, Inc.
NASDAQCrocs stock at $117.54 sits 15.5% below Barclays' new $139 price target after analyst Adrienne Yih upgraded the footwear maker from Equal-Weight to Overweight and lifted her price objective from $118. The upgrade reflects confidence in improving North America fundamentals, lean wholesale inventory positioning for a potential restocking cycle, and multiple brand-specific growth drivers including strong sandal demand and clog innovation. Consensus rating remains Hold at $138.75 mean target. Short interest stands at 9.4% of float, down 6% over the past week, while cost to borrow sits near historical lows at 0.49%.
CROX Barclays upgrades to Overweight, raises target 18% to $139.
Crocs stock at $117.54 sits 15.5% below Barclays' new $139 price target after analyst Adrienne Yih upgraded the footwear maker from Equal-Weight to Overweight and lifted her price objective from $118. The upgrade reflects confidence in improving North America fundamentals, lean wholesale inventory positioning for a potential restocking cycle, and multiple brand-specific growth drivers including strong sandal demand and clog innovation. Consensus rating remains Hold at $138.75 mean target. Short interest stands at 9.4% of float, down 6% over the past week, while cost to borrow sits near historical lows at 0.49%.
Snapshot as of 19 Oct 2026
CROX enters the week having broken from the pack — up 4.7% on Tuesday and 3.9% on the week to $141.19 — while the options market has quietly shifted to its most defensive posture in months. The sharpest signal this…
Crocs managed a 3.5% bounce on July 31st, yet the week still ended 5% lower — and beneath that recovery, short positioning has been drifting higher for a month while the borrow market remains notably loose. The…
Crocs heads into its Q1 2026 earnings report with a notable shift in analyst sentiment colliding with a still-meaningful short position — and the two are pulling in opposite directions. The analyst story is the most…
Crocs enters the post-earnings session in a paradox: the company just delivered one of its cleaner beats in recent memory, yet short sellers spent the past month steadily pressing harder. That tension — a stock up 26%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CROX — free to start on ORTEX.
Sign up for free →Open CROX on ORTEX